Having trouble accessing articles? Reset your cache.

Stem cells (re)generate rewards for Versant, Bayer

A risky bet on BlueRock’s stem cell technology has paid off for Versant and Bayer

The combination of stem cells, gene therapy and regenerative medicine was not in vogue in 2016, but Versant and Bayer felt it had enough promise to make a bet on creating and funding BlueRock.

Now the partners are reaping the benefits of the $225 million series A with which they launched BlueRock Therapeutics L.P. that year.


Read the full 555 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers